Wockhardt gets EIR with observations for 3 plants from USFDA

22 Jul 2016 Evaluate

The US health regulator has made observations in its Establishment Inspection Report (EIR) for Wockhardt’s three units in Maharashtra and ban on exports from the facilities to the US will continue. The company’s three facilities - Chikalthana and two units at Waluj in Maharashtra - have received EIR with observations. EIR is given to an establishment after the completion of the inspection by the US Food and Drug Administration (USFDA).

Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.

Wockhardt Share Price

1429.20 33.15 (2.37%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×